Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$4.89
▲ $0.13 (+2.7%)
Market data updated: 09/20 01:48 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$114.71M
Day Range
$4.71 - $5.08
52-Week Range
$3.71 - $7.75
Beta
—
Next Earnings
10.11.2026
Support
$3.86
Resistance
$5.64
COYA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-14.8% (1Y)
Strengths: 11/26 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 123.6%
Growth
Biggest negative driver
Operating margin
Operating margin: -283.9% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
53
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
today · $4.89
Evidence: FOMO score jumped from 13 to 45 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
46
Quality
42
Value
50
Momentum
74
Risk
40
Sentiment
74
Fundamental
30
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Coya Therapeutics has centered on its preclinical and clinical progress in immunology and neurodegenerative diseases, particularly ALS and brain inflammation. The company highlighted a published study on its lead candidate, COYA 303, showing immunomodulatory effects in inflammation models, while also advancing the Phase 2 ALSTARS ALS trial into a blinded extension phase. Financial updates revealed improved quarterly loss estimates, and analyst optimism was noted, including a "Buy" rating with a $12 price target. Additionally, Coya hosted events on repetitive head trauma and neurodegeneration, reinforcing its focus on inflammatory and neurotherapeutic research.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Coya Therapeutics, Inc.. News trend score: 74. Reason: 6 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
39
🎯 Conviction (vs. Emotion)
48
Psychology
45
Fundamentals
30
Technical
74
Valuation
50
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-1%
Market Narrative
64
Fundamental Reality
48
Narrative Gap
+16
🧠 StockIQ Psychologist
COYA’s psychology profile suggests **herding** as the dominant behavioral force, with traders aligning with peers’ underperformance in the sector. The narrow narrative-reality gap (-1) implies limited misalignment, but the lack of extreme states (e.g., panic or euphoria) hints at cautious, herd-driven positioning. Key uncertainty remains whether this herding reflects rational sector rotation or speculative crowding. The absence of volatility spikes or extreme sentiment extremes further supports a disciplined, not impulsive, behavioral stance. Open question: Is this herding a temporary sector rotation or a deeper trend?
Updated: 09/09/2026, 04:48 AM
What could change this?
👥 What the crowd believes
"Roth Capital reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $12 price target."
"Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting"
"Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65%."
"Coya Therapeutics secures FDA fast track status for COYA 302"
🧠 Market Brain events driving this
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for COYA reflects deep contrasts in how these methodologies prioritize risk, valuation, and market psychology. Walter Bagehot’s near-perfect score highlights his focus on liquidity and resilience, suggesting the stock might weather financial stress—an approach that ignores growth or valuation entirely. Meanwhile, Benjamin Graham’s defensive and enterprising models show moderate interest, as they balance safety with potential undervaluation, though neither sees it as a deep bargain. In contrast, Fisher, Lynch, and Malkiel/Bogle dismiss it outright, emphasizing quality, growth, or efficiency—principles that clash with COYA’s perceived volatility or lack of standout fundamentals. At the other extreme, Veblen and Housel flag it as speculative or emotionally driven, while Schwager’s mechanical discipline outright rejects it as a tradeable setup, underscoring how rigid rule-based systems dismiss what others might tolerate as a niche opportunity.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 74
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 67
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 64
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 51
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 48
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 45
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 44
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 36
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 35
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 35
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 23
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-283.9%
Net Margin
-267.1%
EBITDA Margin
-283.9%
ROE
-49.3%
ROA
-42.5%
ROIC
—
EPS
-$1.27
Cash
$46.82M
Total Debt
—
Current Ratio
8.50
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$2.57
Tangible Book Value per Share (Tangible NAV)
$2.57
Sentiment based on basic keywords (not AI) — 6 positive, 12 neutral, 2 negative out of the last 20 articles.
Benzinga · 15.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
Yahoo · 8.9.2026
Business Wire · 8.9.2026
Benzinga · 8.9.2026
Benzinga · 24.8.2026
Business Wire · 11.8.2026
Benzinga · 11.8.2026
SeekingAlpha · 25.7.2026
Zacks · 30.6.2026
Business Wire · 18.6.2026
Business Wire · 15.6.2026
MT Newswires · 8.6.2026
Business Wire · 8.6.2026
MT Newswires · 5.6.2026
Pharmaceutical Technology · 14.5.2026
Exec Edge · 12.5.2026
Exec Edge · 7.5.2026
Exec Edge · 6.5.2026
Coya Therapeutics, Inc. (COYA) currently has a StockIQ AI score of 53/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
COYA currently scores 53/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
COYA's technical score is 74/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 123.6%; Current ratio: 8.50; Price is above the 50-day average.
Based on the real signals StockIQ computed: Operating margin: -283.9% (negative); Net margin: -267.1% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for COYA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Pavao Mark H | Grant/Award from Employer | 9.4.2026 | 10,000 | +10,000 | — |
| Pavao Mark H | Grant/Award from Employer | 9.4.2026 | 10,000 | +10,000 | — |
| Swaminathan Arun | Grant/Award from Employer | 22.1.2026 | 293,983 | +293,983 | — |
| Berman Howard | Grant/Award from Employer | 22.1.2026 | 15,257 | +15,257 | — |
| Grossman Fred | Grant/Award from Employer | 22.1.2026 | 140,041 | +140,041 | — |
| SNYDER DAVID S | Grant/Award from Employer | 22.1.2026 | 140,041 | +140,041 | — |
| SNYDER DAVID S | Grant/Award from Employer | 22.1.2026 | 140,041 | +140,041 | — |
| Swaminathan Arun | Grant/Award from Employer | 22.1.2026 | 293,983 | +293,983 | — |
| Berman Howard | Grant/Award from Employer | 22.1.2026 | 15,257 | +15,257 | — |
| Grossman Fred | Grant/Award from Employer | 22.1.2026 | 140,041 | +140,041 | — |
| Lee Ann | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| Weinand Dieter | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| ROSS WILBUR L JR | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| GOLDSTEIN DOV A MD | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| Villalobos Anabella | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| ROSS WILBUR L JR | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| GOLDSTEIN DOV A MD | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| Weinand Dieter | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| Lee Ann | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| Villalobos Anabella | Grant/Award from Employer | 2.1.2026 | 10,000 | +10,000 | — |
| GOLDSTEIN DOV A MD | Exercise of Derivative Securities | 18.8.2025 | 17,557 | -17,557 | — |
| GOLDSTEIN DOV A MD | Exercise of Derivative Securities | 18.8.2025 | 17,557 | +17,557 | $1.09 |
| GOLDSTEIN DOV A MD | Exercise of Derivative Securities | 18.8.2025 | 27,557 | +17,557 | $1.09 |
| GOLDSTEIN DOV A MD | Exercise of Derivative Securities | 18.8.2025 | 0 | -17,557 | — |
| Weinand Dieter | Grant/Award from Employer | 25.2.2025 | 5,000 | +5,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
1,085,717 shares short as of 2026-08-31 · vs. 1,072,865 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
48.2% of trading volume this week was short selling, vs. 54.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology